Henry O. Gosebruch
CEO & Executive DirectorMr. Henry O. Gosebruch is Director of ANI Pharmaceuticals, Inc. from August 19, 2026. Mr. Gosebruch served as President, Chief Executive Officer and Director at Neumora Therapeutics, Inc. since July 2023 until February 14, 2025. He joined Neumora in July 2023 He serves as an Independent Director at Acelyrin, Inc. since March 17, 2023. He served as the Chief Strategy Officer and Executive Vice President at AbbVie Inc. since 2015 until February 2023, where he was responsible for corporate strategy, business development and acquisitions, search and evaluation, alliance management, early-stage collaborations and the corporate strategic venture capital arm, AbbVie Ventures. Prior to AbbVie since 2015, Mr. Gosebruch worked in the Mergers & Acquisitions Group at J. P. Morgan Securities LLC, serving as Managing Director since 2007 and as Co-Head of M&A North America during 2015. He served as an Independent Director of Aptinyx Inc. since May 6, 2019 until May 04, 2023. Mr. Gosebruch serves as a Member of the Advisory Board for the Life Sciences & Management Program at the University of Pennsylvania. He received B.S. in Economics from the Wharton School at the University of Pennsylvania and is a Certified Public Accountant (CPA) in Illinois.
Positions
- Company NameLakefront Biotherapeutics NVStock CodeLKFTPositionCEO & Executive DirectorColleagues
- GSGino SantiniIndependent Non-Executive Chairman
- ALAaron L. CoxChief Financial Officer
- CCChristina CarlsonChief Operating Officer
- GSGlenn SchulmanHead of Investor Relations
- FWFred W. BlakesleeExecutive VP & General Counsel
- JVJane Veronica GriffithsNon-Executive Independent Director
- DADawn A. SvoronosNon-Executive Independent Director
- NGNeil G. JohnstonNon-Executive Independent Director
